학술논문
Dolutegravir: an exciting new kid on the block
Document Type
Article
Source
Expert Opinion on Pharmacotherapy; March 2014, Vol. 15 Issue: 4 p573-582, 10p
Subject
Language
ISSN
14656566; 17447666
Abstract
Introduction:Dolutegraviris the first second-generation integrase inhibitor approved for the treatment of naïve as well as experienced HIV-infected individuals.Areas covered:Data from pharmacokinetics, efficacy, safety, tolerability and resistance are reviewed from in vitrostudies, Phase II and III clinical trials published in PubMed (Dolutegravir; S/GSK1349572) or presented in international meetings.Expert opinion:Data from studies and clinical trials indicate that dolutegravir is safe, well tolerated and highly efficacious in the treatment of both antiretroviral-naïve and treatment-experienced patients and appears to have a higher genetic barrier to resistance than first-generation integrase inhibitors.